Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04798287
Registration number
NCT04798287
Ethics application status
Date submitted
11/03/2021
Date registered
15/03/2021
Date last updated
22/06/2022
Titles & IDs
Public title
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
Query!
Scientific title
Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints
Query!
Secondary ID [1]
0
0
2011P002580-207
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
STAR-RA-Cancer
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tofacitinib
Treatment: Drugs - TNF Inhibitor
Patients treated with Tofacitinib - Real-World Evidence (RWE) and RCT-Duplicate
Patients treated with TNF inhibitors - Real-World Evidence (RWE) and RCT-Duplicate
Treatment: Drugs: Tofacitinib
First eligible prescription for treating rheumatoid arthritis (RA)
Treatment: Drugs: TNF Inhibitor
First eligible prescription for treating rheumatoid arthritis (RA)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to second outpatient or inpatient diagnosis of any cancer (excluding NMSC and any carcinoma in situ diagnosis)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [1]
0
0
Time to second outpatient or inpatient diagnosis of lung cancer (excluding any carcinoma in situ diagnosis)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [2]
0
0
Time to second outpatient or inpatient diagnosis of colorectal cancer (excluding any carcinoma in situ diagnosis)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [3]
0
0
Time to second outpatient or inpatient diagnosis of breast cancer (excluding any carcinoma in situ diagnosis)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [4]
0
0
Time to second outpatient or inpatient diagnosis of prostate cancer (excluding any carcinoma in situ diagnosis)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [5]
0
0
Time to second outpatient or inpatient diagnosis of lymphatic/hematopoietic tissue cancers
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [6]
0
0
Time to second outpatient or inpatient diagnosis of lymphoma
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [7]
0
0
Time to second outpatient or inpatient diagnosis of leukemia
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Through study time period (2012-2020)
Query!
Secondary outcome [8]
0
0
Time to first procedure code occurring within 60 days of an outpatient or inpatient diagnosis of NMSC
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Through study time period (2012-2020)
Query!
Eligibility
Key inclusion criteria
Criteria:
Please see https://www.bwhprime.org/resources.html for full code and algorithm definitions.
Eligible cohort entry dates:
- For US MarketScan, 2012-2018
- For Optum, 2012-2020
- For Medicare Claims Database (Parts A, B and D), 2012-2017
Cohort entry date:
- First TNFi or tofacitinib dispensation/administration date
Inclusion and
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria Common to RWE and RCT-duplicate Cohorts:
1. Inclusion Criteria
- Patients treated with tofacitinib or TNF inhibitors in IBM MarketScan, Optum, and
Medicare fee-for-service
- A minimum of 365 days of continuous enrollment in health plan prior to (and
including) the cohort entry date
- Two diagnosis codes for RA in any setting in 365 days baseline period (diagnosis
codes between 7 and 365 days apart)
2. Exclusion Criteria
- Index drug in 365 days prior to cohort entry date (prevalent users)
- Missing data on age or gender
- Admission to nursing facility or hospice on or prior to cohort entry date (ever
look-back)
- Diagnosis of malignant cancer prior to cohort entry date (ever look-back period)
- TNFi users with history of any Janus kinase (JAK) inhibitors (tofacitinib,
upadacitinib, or baricitinib) (ever look-back period)
- TNFi users initiating with more than one TNFi on same date
- Tofacitinib users with a prescription of baricitinib, upadacitinib (ever
look-back period)
- Tofacitinib users initiating treatment on multiple JAK inhibitors on same day
(tofacitinib and baricitinib, tofacitinib and upadacitinib)
Exclusion criteria specific to RWE cohorts:
- Patients less than 18 years of age (MarketScan and Optum) and 65 years of age
(Medicare) at cohort entry
Inclusion criteria specific to RCT-duplicate cohorts:
- Patients with at least one methotrexate dispensation (six months look-back period)
- Patients with at least one cardiovascular risk factor (including smoking,
hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, family history
of ischemic heart disease) (one-year look-back period)
Exclusion criteria specific to RCT-duplicate cohorts:
- Patients less than 50 years of age (MarketScan and Optum) and 65 years
- Patients recently hospitalized with infections (30-day look-back period)
- Pregnant patients (one year look-back period)
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Retrospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/03/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/05/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
105711
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Massachusetts
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Brigham and Women's Hospital
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
There are two main aims of this study.
First aim is to compare the risk of composite cancer outcomes, between patients treated with
tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA)
among, 1) "real world evidence (RWE)" cohorts including routine care patient population from
the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohorts including routine care
patient population who meet inclusion and exclusion criteria of the Safety Study Of
Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid
Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.
Second aim is to examine the risk of common solid cancers (lung, colorectal, breast,
prostate), hematological cancers, and non-melanoma skin cancer as separated endpoints when
comparing tofacitinib with TNFi in patients with RA among, 1) "real world evidence (RWE)"
cohort including routine care patient population from the US and, 2) "Randomized controlled
trial (RCT) DUPLICATE" cohort including routine care patient population who meet inclusion
and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF)
Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical
trial.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04798287
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Seoyoung C Kim, MD, ScD, MSCE
Query!
Address
0
0
Brigham and Women's Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04798287
Download to PDF